E.K. Almaz

E.K. Almaz

Auto-generated profile, based on publicly available information

E.K. Almaz

Research Institute for Biological Safety Problems, Ministry of Health of the Republic of Kazakhstan, Gvardeysky Settlement, Korday District, Zhambyl Region, Republic of Kazakhstan; National Holding “QazBioPharm”, Republic of Kazakhstan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Eurasian Journal of Applied Biotechnology
Verified
Journal Article
Open access
PDF file
AAA.B. Aliyeva
A.B. Aliyeva
DAD.B. Aidarbekova
D.B. Aidarbekova
EAE.K. Almas
E.K. Almas
OSO.N. Serikbayov
O.N. Serikbayov
KBK.B. Barakbayev
K.B. Barakbayev
EAE.O. Abduraymov
E.O. Abduraymov
This study presents the results of sheep pox monitoring conducted by the Research Institute for Biological Safety Problems (RIBSP) in the Republic of Kazakhstan. To study the epizootic situation of sheep pox, several field expeditions were organized to 15 regions of the country. The primary objectives of the monitoring were to assess the prevalence of the sheep pox virus among small ruminants, identify potential infection foci, and analyze the level of animal immunity. This is due to the paramount importance of controlling the epizootic situation, timely detection of outbreaks, and development of veterinary and sanitary measures for forecasting the spread of sheep pox. The samples were collected from 240 rural districts within 82 rayons (or settlements/farms) across 15 regions of Kazakhstan: Zhambyl, Karaganda, Kyzylorda, Turkestan, Almaty, Zhetysu, Abay, Akmola, West Kazakhstan, Aktobe, North Kazakhstan, East Kazakhstan, Pavlodar, Atyrau, and Mangystau. Sheep blood serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) for antibodies to the sheep pox virus. The monitoring revealed an uneven distribution of immune animals to the sheep pox virus in Kazakhstan. In the Abay, East Kazakhstan, Aktobe, and Pavlodar regions, no serologically positive animals were detected, indicating the absence of post-vaccination immunity. A low level of immunity was registered in the Akmola, Karaganda, West Kazakhstan, North Kazakhstan, Mangystau, and Atyrau regions. In contrast, the Zhambyl, Turkestan, Almaty, and Zhetysu regions demonstrate the presence of an immune background against sheep pox.

31 August 2024 in Eurasian Journal of Applied Biotechnology
Verified
Journal Article
Open access
PDF file
AAA.B. Aliyeva
A.B. Aliyeva
DAD.B. Aidarbekova
D.B. Aidarbekova
KBK.B. Barakbayev
K.B. Barakbayev
EAE.K. Almaz
E.K. Almaz
OSO.N. Serikbayov
O.N. Serikbayov
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
The article presents the results of research on the choice of a stabilizer for strains "CP-65K" and "BIEMG-51" orthopoxviruses, which helps to preserve their biological activity during lyophilization, storage in various temperature and time conditions and transportation. To select a stabilizing medium that ensures the greatest preservation of the virus during lyophilization and subsequent storage, depending on the composition of protective media, temperature and shelf life, we prepared 3 samples of each vaccine preparation with stabilizing additives: I and V samples consisted of 5 % peptone and 3 % sucrose; II and VI samples - of 3 % peptone and 2 % sucrose; III and VII samples - from skimmed milk; IV and VIII samples - control. All protective media were added to the viral materials in a 1:1 ratio. As a result of the conducted studies, it was found that of the tested samples of stabilizing media, the most protective property for the strains «CP-65K» CPOX and "BIEMG-51" smallpox vaccine virus had a stabilizing medium consisting of a mixture of peptone (5 %) and sucrose (3 %) in the final concentration, which ensured the safety of vaccine strains for 12 months month. at a temperature of (2-8) °C and minus (40.0±1.0) °C without a significant decrease in their biological activity (6.50±0.14 lg TCID50/cm3 and 6.25±0.14 lg TCID50/cm3, respectively).

17 July 2025 in Biosafety and Biotechnology
Verified
Journal Article
Open access
PDF file
KBK. B. Barakbayev
K. B. Barakbayev
AAA. B. Alieva
A. B. Alieva
OSO. N. Serikbayov
O. N. Serikbayov
DAD. B. Aidarbekova
D. B. Aidarbekova
EAE. K. Almas
E. K. Almas
The article presents the results of a study on the safety and immunogenicity of monoand polyvalent vaccines designed for the specific prevention of pasteurellosis in animals, based on the genetically attenuated strain of P. multocida Aro/A serotype B.The monovalent vaccine, made from P. multocida serotype B, was administered to calves in a dose of 2.5x108 CFU (colony-forming units), and to sheep and goats in a dose of 2.5x109 CFU. The polyvalent vaccine, containing a genetically attenuated strain of P. multocida Aro/A and microbial cells of P. multocida serotype D in equal proportions (1:1), was administered to calves and piglets in a dose of 2.5x108 CFU, and to sheep and goats in a dose of 2.5x109 CFU.To evaluate the immunogenicity of the vaccines, animals were infected with the epizootic strain of P. multocida T88 on the 28th day after vaccination. Following infection, no signs of pasteurellosis were observed in any of the experimental animals: there were no indications of pain, redness or rashes at the body and injection sites, weakness, coughing, or elevated body temperature.The results of the conducted studies confirm the safety and immunogenicity of the mono- and polyvalent vaccines prepared from the attenuated strain of P. multocida Aro/A for animals.

30 April 2026 in Наука и здравоохранение
Verified
Journal Article
Open access
PDF file
АААlina Аliyeva
Аlina Аliyeva
DADinara Aidarbekova
Dinara Aidarbekova
EAErmukhan Almas
Ermukhan Almas
OSOrazbek Serikbayov
Orazbek Serikbayov
KBKainar Barakbayev
Kainar Barakbayev
AKAslan Kerimbaev
Aslan Kerimbaev
Background. The current stage in the development of immunoprophylaxis is characterized by the search for technologies capable of ensuring broad population coverage while maintaining vaccine efficacy and safety. Alongside the development of novel antigen platforms, increasing attention is being paid to the optimization of dosage forms and routes of administration. Practical interest in needle-free approaches is driven by the need to simplify immunization procedures, reduce the organizational burden on healthcare systems, and improve access to preventive interventions in settings with limited infrastructure. Oral formulations in tablet form represent one of the directions integrating pharmaceutical and immunological strategies. Their development is associated with the potential to induce mucosal immune responses while simultaneously enhancing ease of administration. In this context, an analysis of current research focused on the development and clinical evaluation of tablet-based vaccines is of both scientific and practical relevance. Objective. To conduct a systematic analysis of domestic and international publications addressing the development, technological features, and clinical evaluation of tablet-based vaccines, and to define their prospects and limitations within contemporary immunoprophylaxis systems. Search Strategy. This study was conducted as a descriptive review. A comprehensive literature search was performed using international and national databases, including PubMed, Scopus, Web of Science, the Cochrane Library, eLIBRARY, and Google Scholar. Search terms reflected the scope of oral and mucosal immunization. In addition, official reports of international organizations and data from clinical trial registries were examined. Publications containing experimental and clinical data on the development and application of oral and tablet-based vaccines were considered eligible for inclusion. The search covered the period from 1970 to 2024. The selected timeframe reflects the active development of oral vaccines in the second half of the twentieth century and the subsequent accumulation of contemporary data on mucosal immunity, antigen stabilization technologies, and delivery systems. The initial search identified more than 150 publications. After removal of duplicate records and screening of titles and abstracts, studies specifically addressing tablet-based and oral vaccines were selected for full-text review. A total of 89 publications demonstrating scientific relevance and providing sufficient experimental or clinical data were included in the final analysis. Results. The analysis of the literature indicates that tablet-based vaccines have the potential to induce both systemic and mucosal immune responses. Their use may facilitate immunization procedures, reduce organizational costs, and expand population coverage. At the same time, further development in this field requires addressing challenges related to antigen stabilization, the design of effective delivery systems, and the accumulation of robust clinical evidence. Conclusion. Tablet-based vaccines represent an emerging direction in needle-free immunization with the potential to complement existing vaccination strategies. Continued technological refinement and well-designed clinical studies will be essential to determine their role within modern immunoprophylaxis programs. Актуальность. Современный этап развития иммунопрофилактики характеризуется поиском технологий, способных обеспечить высокий охват населения при сохранении эффективности и безопасности вакцинации. Наряду с созданием новых антигенных платформ, всё большее значение приобретает совершенствование лекарственных форм и путей введения вакцин. Практический интерес к безыгольным методам связан с необходимостью упрощения процедур иммунизации, снижением организационной нагрузки на систему здравоохранения и повышением доступности профилактических мероприятий в условиях ограниченной инфраструктуры. Пероральные препараты в таблетированной форме рассматриваются как одно из направлений, объединяющих фармацевтические и иммунологические подходы. Их разработка связана с возможностью индукции мукозального иммунного ответа и одновременного повышения удобства применения. В этой связи анализ современных исследований, посвящённых созданию и клинической оценке таблетированных вакцин, представляет научный и практический интерес. Цель исследования – провести систематизированный анализ отечественных и зарубежных публикаций, посвящённых разработке, технологическим особенностям и клинической оценке таблетированных вакцин, а также определить их перспективы и ограничения в современной системе иммунопрофилактики. Стратегия поиска. Работа выполнена в формате описательного обзора. Поиск...